Emily Minkow
Corporate Officer/Principal bij PREVAIL THERAPEUTICS INC.
Profiel
Emily Minkow is currently the Director at Stylus Medicine, Inc. and a Venture Partner at RA Capital Management LP (Private Equity).
She was previously the Chief Business Officer at Prevail Therapeutics, Inc. and the Executive Director-Business Development at Celgene Corp.
Ms. Minkow received her undergraduate degree from Princeton University and her MBA from Harvard Business School.
Actieve functies van Emily Minkow
| Bedrijven | Functie | Begin |
|---|---|---|
| PREVAIL THERAPEUTICS INC. | Corporate Officer/Principal | 01-11-2018 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Private Equity Investor | 01-01-2022 |
Stylus Medicine, Inc.
 Stylus Medicine, Inc. Medical SpecialtiesHealth Technology Stylus Medicine, Inc. is a company focused on developing innovative solutions to combat diseases using cutting-edge genome engineering and chromatin regulation technologies. Stylus Medicine is based in Boston, MA. The company is backed by RA Ventures and Khosla Ventures. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Emily Minkow
| Bedrijven | Functie | Einde |
|---|---|---|
| CELGENE | Corporate Officer/Principal | 01-10-2017 |
Opleiding van Emily Minkow
| Harvard Business School | Masters Business Admin |
| Princeton University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Prevail Therapeutics, Inc.
 Prevail Therapeutics, Inc. BiotechnologyHealth Technology Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The firm engages in the research and development of novel biologic gene therapies to treat Parkinson's disease and other neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY. | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
Stylus Medicine, Inc.
Stylus Medicine, Inc. Medical SpecialtiesHealth Technology Stylus Medicine, Inc. is a company focused on developing innovative solutions to combat diseases using cutting-edge genome engineering and chromatin regulation technologies. Stylus Medicine is based in Boston, MA. The company is backed by RA Ventures and Khosla Ventures. | Health Technology |
